MCRB Seres Therapeutics
- 0.820
- -0.027-3.19%
Seres Therapeutics News
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics Analyst Ratings
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Buy Rating Affirmed for Seres Therapeutics Amid Strong Clinical Outcomes for SER-155
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics (MCRB) Gets a Hold From Oppenheimer
Buy Rating on Seres Therapeutics: Strategic Growth and Promising Clinical Trials Fuel Analyst Confidence
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Strong Sales and Promising Trials Underpin Buy Rating for Seres Therapeutics
Seres Therapeutics Analyst Ratings
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
Analysis
Price Target
No Data
No Data